In this post, the Pharma in Brief team reports on two recent developments in the Quebec regulatory landscape related to the COVID-19 crisis.
Adjustments to submission procedure for applications for listing of innovative drugs and blood products on formulary
On April 6, 2020, Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) issued a notice to drug manufacturers and blood system product manufacturers describing temporary measures implemented recently to avoid processing backlogs for applications for listing on Quebec's formulary during the COVID-19 crisis. As of March 30, 2020, manufacturers of innovative drugs or blood products can submit their registration applications to INESSS electronically through the Ministry of Health and Social Services' secure ShareFile platform. This change does not apply to the submission procedure for manufacturers of generic drugs or natural health products. Moreover, no pre-submission or post-submission meetings shall take place in person until further notice. Teleconference meetings are allowed.
New clinical trial for potential COVID-19 treatment
On March 23, 2020, the Quebec government, with partners in industry and academia, launched a clinical trial called COLCORONA, aiming to assess a short-term treatment's ability to reduce the rate of death and lung complications related to COVID-19. Researchers for this randomized, double-blind, placebo-controlled study seek the enrollment of 6,000 participants aged 40 or over, who have been diagnosed with COVID-19 and have not been hospitalized.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
nortonrosefulbright.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
